In one study, the median overall survival after BM from breast cancer was 11.5 months, and while the treatment outcome differed among cancer subtypes (ER, PR, Her2 status), focal brain treatment could be considered for better local control of BM in patients with aggressive subtypes [10]. This evidence concerns the gene ERBB2 and cancer.